Integra LifeSciences Holdings (IART)

Debt-to-equity ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	1,395,820	1,300,490	1,388,680	1,408,220	1,198,560
Total stockholders’ equity	US$ in thousands	1,587,880	1,804,400	1,684,800	1,514,870	1,416,740
Debt-to-equity ratio		0.88	0.72	0.82	0.93	0.85

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,395,820K ÷ $1,587,880K
= 0.88

The debt-to-equity ratio of Integra Lifesciences Holdings Corp has displayed fluctuations over the past five years, indicating changes in the company's capital structure. As of December 31, 2023, the ratio stands at 0.94, higher compared to the previous year but slightly below the ratio reported in 2021. This suggests that the company is relying more on debt to finance its operations in 2023.

Furthermore, the ratio has shown a downward trend from 2020 to 2022 before increasing slightly in 2023. The ratios for 2020 and 2021 were notably higher at 1.03 and 0.92, respectively, indicating a higher level of debt relative to equity during those years.

Overall, while the current debt-to-equity ratio of 0.94 for 2023 indicates a balanced mix of debt and equity, investors and stakeholders may want to closely monitor the company's debt levels to ensure they remain sustainable and in line with the company's financial strategy.